Other secondary endpoints
DISEASE PROGRESSION
To assess glycemic control, we measured glycated haemoglobin (HbATo examine the usage of exogenous insulin in order to maintain glycemic control, we conducted analyses to evaluate the change of total daily insulin use. At baseline, total daily insulin use was 0.25, 0.24 and 0.23 U/kg/day for the saxagliptin plus vitamin D, the saxagliptin and the conventional therapy group, respectively. The total daily insulin use increased 30% in the conventional therapy group that was concordant with the disease progression, whereas the increases were only 4.2% in both saxagliptin plus vitamin D and saxagliptin alone groups (